Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues A, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Welsh P, Kean S, Ford I, McConnachie A, Messow C-M, Sattar N, Taylor R. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. The Lancet Diabetes & Endocrinology 2019:6 de marzo. [Ref.ID 103052]

Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med 2019;380:7 de febrero. [Ref.ID 103035]

Jones G. GW Pharma's cannabis-based medicine to be tested in dementia. PMLiVE 2019:1. [Ref.ID 103025]

Taylor P. Finch’s microbiota drug for C. diff gets FDA breakthrough status. PMLiVE 2019:11 de febrero. [Ref.ID 103019]

Attia E, Steinglass JE, Walsh BT, Wang Y, Wu P, Schreyer C, Wildes J, Yilmaz Z, Guarda AS, Kaplan AS, Marcus MD. Olanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial. Am J Psychiatry 2019:18 de enero. [Ref.ID 103015]

Young K. Diabetes guidelines updated. Journal Watch 2018:1. [Ref.ID 102893]

Girard TD , Exline MC , Carson SS , Hough CL , Rock P , Gong MN , Douglas IS , Malhotra A , Owens RL , Feinstein DJ , Khan B , Pisani MA , Hyzy RC , Schmidt GA , Schweickert WD , Hite RD , Bowton DL , Masica AL , Thompson JL , Chandrasekhar R , Pun BT , Strength C , Boehm LM , Jackson JC , Pandharipande PP , Brummel NE , Hughes CG , Patel MB , Stollings JL , Bernard GR , Dittus RS , Ely EW , for the MIND-USA Investigators. Haloperidol and ziprasidone for treatment of delirium in vritical illness. N Engl J Med 2018;379:22 de octubre. [Ref.ID 102838]

Chapman KR, Hurst JR, Frent SM, Larbiq M, Fogel R, Guerin T, Banerji D, Patalano F, Goyal P, Pfister P, Kostikas K, Wedzicha JA. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med 2018;198:1 de agosto. [Ref.ID 102826]

Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ 2018;362:k2693. [Ref.ID 102821]

Meltzer AC, Burrows PK, Wolfson AB, Hollander JE, Kurz M, Kirkali Z, Kusek JW, Mufarrij P, Jackman SV, Brown J. Effect of tamsulosin on passage of symptomatic ureteral stones. A randomized clinical trial. JAMA Intern Med 2018;178:1051-7. [Ref.ID 102775]

Datta R, Juthani-Mehta M. Nitrofurantoin vs fosfomycin. Rendering a verdict in a trial of acute uncomplicated cystitis. JAMA 2018;319:1 de junio. [Ref.ID 102767]

Sénat M-V, Affres H, Letourneau A, Coustols-Valat M, Cazaubiel M, Legardeur H, Jacquier JF, Bourcigaux N, Simon E, Rod A, Héron I, Castera V, Sentilhes L, Bretelle F, Rolland C, Morin M, Deruelle P, De Carne C, Maillot F, Beucher G, Verspyck E, Desbriere R, Laboureau S, Mitanchez D, Bouyer J, for the Groupe de Recherche en Obstétrique et Gynécologie (GROG). Effect of glyburide vs subcutaneous insulin on perinatal complications among women with gestational diabetes. A randomized clinical trial. JAMA 2018;319:1 de junio. [Ref.ID 102766]

Coustan DR, Barbour L. Insulin vs glyburide for gestational diabetes. JAMA 2018;319:1 de junio. [Ref.ID 102765]

Palmer SC, Strippoli GFM. Metformin as first-line treatment for type 2 diabetes . Lancet 2018;392:14 de julio. [Ref.ID 102743]

Anónimo. EMA’s CHMP recommends approval for plaque psoriasis drug. DIA Daily 2018:4. [Ref.ID 102730]

Garde D. Alzheimer’s study sparks a new round of debate over the amyloid hypothesis. STAT Daily Recap 2018:30 de julio. [Ref.ID 102727]

Garde D. Experimental Alzheimer’s drug significantly slowed patients’ cognitive decline, buoying hopes for treatment. STAT Daily Recap 2018:1. [Ref.ID 102726]

Garde D. Biogen reports positive results with Alzheimer’s drug, reviving hopes for once-failed treatment. STAT Daily Recap 2018:1. [Ref.ID 102725]

Anónimo. Synthetic cannabinoid may improve agitation and aggression in Alzheimer’s disease patients, research suggests. DIA Daily 2018:26 de julio. [Ref.ID 102724]

Anónimo. CDC says multiple doses of naloxone needed for overdoses linked to fentanyl. DIA Daily 2018:8. [Ref.ID 102713]